EUVIMEDEUVIMED entdecken
Übersichtsarbeit

An update on the treatment paradigm for non-clear cell renal cell carcinoma

Alessandro Rametta iD, Noemi Crippa, Simone Rota, Eleonora Gusmaroli, Marco Stellato iD, Elena Verzoni, Amedeo Nuzzo, Melanie Claps, Valentina Guadalupi, Giuseppe Procopio

Expert Review of Clinical Pharmacology · 2026

DOI: 10.1080/17512433.2026.2615995 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2026. Verfasst von Alessandro Rametta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Agents. Die Arbeit nennt 98 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Non - clear cell renal cell carcinoma (nccRCC) encompasses a heterogeneous group of rare malignancies, representing approximately 20-25% of all renal cancers. Unlike clear cell RCC (ccRCC), these subtypes - papillary, chromophobe, collecting duct, translocation, molecularly defined variants and others - display distinct biological behaviors, genetic profiles, and therapeutic sensitivities, which preclude a uniform treatment approach. AREAS COVERED: This review provides an updated overview of systemic therapy for nccRCC, integrating evidence from prospective trials, retrospective series, and translational research. For most of these histologies, immune checkpoint inhibitor (ICI) - based combinations (e.g. pembrolizumab - lenvatinib, nivolumab - cabozantinib or nivolumab-ipilimumab) have demonstrated the best activity. In chromophobe RCC (chRCC), also mechanistic target of rapamycin (mTOR) inhibition appears particularly relevant, whereas in collecting duct carcinoma and renal medullary carcinoma platinum-based chemotherapy continue to have an important role, with cabozantinib showing encouraging results. Novel biomarker-driven approaches are emerging for selected molecular subsets. EXPERT OPINION: Although remarkable progress has been achieved, the optimal therapeutic strategy for nccRCC remains undefined. Future efforts should focus on histology- and biomarker-driven clinical trials, molecular stratification, to optimize efficacy across subtypes. International collaboration is crucial to overcome the challenges posed by the rarity and biological heterogeneity of these tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAntineoplastic AgentsHumansBiomarkers, TumorImmune Checkpoint InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsTranslational Research, Biomedical

Stichwörter der Autor:innen

Non–clear cell renal cell carcinomachromophobe RCCcollecting duct carcinomaimmunotherapypapillary RCCrare kidney cancertranslocation RCCvascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-T…

Substanzen

Biomarkers, TumorImmune Checkpoint InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

ORCID-Profile: Alessandro Rametta, Marco Stellato

Zitieren

APA

Rametta, A., Crippa, N., Rota, S., Gusmaroli, E., Stellato, M., Verzoni, E., Nuzzo, A., Claps, M., Guadalupi, V., & Procopio, G. (2026). An update on the treatment paradigm for non-clear cell renal cell carcinoma. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2026.2615995

Vancouver

Rametta A, Crippa N, Rota S, Gusmaroli E, Stellato M, Verzoni E, et al. An update on the treatment paradigm for non-clear cell renal cell carcinoma. Expert Review of Clinical Pharmacology. 2026. doi:10.1080/17512433.2026.2615995

BibTeX
@article{Rametta2026,
  author = {Rametta, Alessandro and Crippa, Noemi and Rota, Simone and Gusmaroli, Eleonora and Stellato, Marco and Verzoni, Elena and Nuzzo, Amedeo and Claps, Melanie and Guadalupi, Valentina and Procopio, Giuseppe},
  title = {An update on the treatment paradigm for non-clear cell renal cell carcinoma},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2026},
  doi = {10.1080/17512433.2026.2615995}
}
Kostenlos starten →